SR1375: Phase 1 results of a novel, orally administered lipoprotein‐associated phospholipase A2 inhibitor targeting diabetic macular oedema

医学 药代动力学 耐受性 安慰剂 药效学 药理学 糖尿病性视网膜病变 胃肠病学 内科学 泌尿科 内分泌学 糖尿病 不利影响 病理 替代医学
作者
Yanan Hu,Xuechun Gong,Shiping Ma,Ruxing Bai,Pan Wang,Hong Li,Mingyue Wu,Yang Li,Fei Wang,Shuai Li,Kai Wu
出处
期刊:Acta Ophthalmologica [Wiley]
卷期号:102 (S279)
标识
DOI:10.1111/aos.15880
摘要

Aims/Purpose: Lipoprotein‐associated phospholipase A2 (Lp‐PLA 2 ) activity have been linked to a higher risk of diabetic retinopathy and inhibiting Lp‐PLA 2 activity showed improvement in vision and macular oedema for patients with diabetic macular oedema (DME). SR1375 is an orally available, selective inhibitor of Lp‐PLA2 that shows significant retinal vascular leakage reduction in preclinical studies, and is being developed for DME. A phase 1, randomized, double‐blind, placebo‐controlled study is conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SR1375 in healthy subjects. Methods: A total of 72 healthy subjects were enrolled, with 54 had received SR1375. 48 subjects were in the single ascending dose arms (1, 3, 10, 30, 100 and 200 mg) while 24 subjects were in the multiple ascending dose arms (5, 15 and 50 mg once daily for 14 days). Results: SR1375 was safe and well tolerated across all doses. It had excellent oral absorption with the exposure level increasing in an approximately dose proportional manner after single and multiple doses. The elimination of SR1375 was slow with a long t 1/2 ranging from 28.8 to 90.0 h. The accumulation of SR1375 was not significant after multiple administrations. The plasma inhibition on Lp‐PLA 2 activity by SR1375 was strong (up to 95%) and enduring, which was correlated with the concentration of SR1375 (IC 50 as 1.41 ng/mL) and almost returned to basal level when the concentration of SR1375 was low enough. Conclusions: SR1375 was safe and effective in inhibiting plasma Lp‐PLA 2 . The safety and PK/PD profile supports the once daily therapy. A Phase 2 study for DME patients is planned later this year. It would be a 12‐week randomized, double‐blind and placebo‐controlled trial. The primary objective is to assess the effect of SR1375 on vision and oedema.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李瑞程发布了新的文献求助10
1秒前
充电宝的应助被Xiaodan采纳,获得10
2秒前
3秒前
李瑞程发布了新的文献求助10
3秒前
3秒前
lmy的应助被陈建采纳,获得10
3秒前
Hello的应助被牧百川采纳,获得10
3秒前
3秒前
w57发布了新的文献求助10
4秒前
hy发布了新的文献求助10
4秒前
4秒前
李瑞程发布了新的文献求助10
4秒前
李瑞程发布了新的文献求助10
4秒前
4秒前
烟花的应助被Flora采纳,获得10
4秒前
小梅同学发布了新的文献求助10
5秒前
5秒前
我是老大的应助被热情的远锋采纳,获得10
5秒前
6秒前
d5hh完成签到,获得积分10
6秒前
大个的应助被危言丶采纳,获得10
6秒前
6秒前
等待的秋双完成签到,获得积分10
6秒前
7秒前
李瑞程发布了新的文献求助10
7秒前
7秒前
7秒前
李瑞程发布了新的文献求助10
7秒前
7秒前
李瑞程发布了新的文献求助10
7秒前
李瑞程发布了新的文献求助30
7秒前
tantan发布了新的文献求助10
8秒前
8秒前
求助发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
Lisa的应助被sleblueep采纳,获得10
10秒前
SFF发布了新的文献求助10
10秒前
李瑞程发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183298
求助须知:如何正确求助?哪些是违规求助? 9572606
关于积分的说明 21826444
捐赠科研通 7780272
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558136
邀请新用户注册赠送积分活动 2480259